Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | DRD3 | P35462 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | ACHE | P22303 | 2/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.67 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.67 |
| ▸ | HTR3B | O95264 | 1/20 | 0.67 |
| ▸ | MPO | P05164 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | DRD4 | P21917 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | HTR3A | P46098 | 1/20 | 0.67 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5925506 | 0.96 | ADRA2A (0.63) | LMNAADRA2ACYP2D6DRD3CYP1A2 | |
| SCHEMBL3762394 | 0.89 | ALDH1A1 (0.54) | LMNAADRA2ACYP2D6DRD3CYP1A2 | |
| SCHEMBL1186372 | 0.89 | MCHR1 (0.60) | LMNAADRA2ACYP2D6DRD3CYP1A2 | |
| SCHEMBL1186889 | 0.88 | CYP2D6 (0.57) | LMNAADRA2ACYP2D6DRD3CYP1A2 | |
| SCHEMBL1186887 | 0.87 | LMNA (0.53) | LMNAADRA2ACYP2D6DRD3CYP1A2 | |
| SCHEMBL6108941 | 0.87 | MCHR1 (0.57) | LMNAADRA2ACYP2D6DRD3CYP1A2 | |
| SCHEMBL3414717 | 0.85 | MCHR1 (0.65) | LMNAADRA2ACYP2D6DRD3CYP1A2 | |
| SCHEMBL11755479 | 0.84 | ALDH1A1 (0.70) | LMNAADRA2ACYP2D6DRD3CYP1A2 | |
| SCHEMBL3760672 | 0.84 | ALDH1A1 (0.50) | LMNAADRA2ACYP2D6DRD3CYP1A2 | |
| Dimethylamine SCHEMBL6109558 | 0.83 | ALDH1A1 (0.64) | LMNAADRA2ACYP2D6DRD3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060110743-A1 | Drug evolution: drug design at hot spots | KONISHI YASUO | 2006-05-25 | — | — | US | claimed |
| WO-2002095393-A2 | DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-11-28 | — | — | WO | claimed |
| US-20110052492-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2011-03-03 | — | — | US | disclosed |
| US-20110052492-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2011-03-03 | — | — | US | disclosed |
| US-20110052492-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2011-03-03 | — | — | US | disclosed |
| US-20110027179-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2011-02-03 | — | — | US | disclosed |
| US-20110027179-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2011-02-03 | — | — | US | disclosed |
| US-20110027179-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2011-02-03 | — | — | US | disclosed |
| US-7850948-B2 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AG (DE) | 2010-12-14 | — | — | US | disclosed |
| US-7850948-B2 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AG (DE) | 2010-12-14 | — | — | US | disclosed |
| US-7850948-B2 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AG (DE) | 2010-12-14 | — | — | US | disclosed |
| EP-1722827-A2 | RADIOHALOGENATED BENZAMIDE DERIVATIVES AND THEIR USE IN TUMOR DIAGNOSIS AND TUMOR THERAPY | Schering AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| US-20060235035-A1 | Novel methoxybenzamibe compounds for use in mch receptor related disorders | 7TM PHARMA A/S (DK) | 2006-10-19 | — | — | US | disclosed |
| US-20060110743-A1 | Drug evolution: drug design at hot spots | KONISHI YASUO | 2006-05-25 | — | — | US | disclosed |
| WO-2005089815-A2 | RADIOHALOGENATED BENZAMIDE DERIVATIVES AND THEIR USE IN TUMOR DIAGNOSIS AND TUMOR THERAPY | SCHERING AG (DE) | 2005-09-29 | — | — | WO | disclosed |
| US-20050207972-A1 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
| EP-1497260-A1 | NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM Pharma A/S (DK) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004048319-A1 | NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003087045-A1 | NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2003-10-23 | — | — | WO | disclosed |
| WO-2002095393-A2 | DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110027179-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | BRDT, AADAC, IDH2 | LMNA 3376/4885ADRA2A 908/4885CYP2D6 373/4885 |
| US-20110052492-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | BRDT, AADAC, IDH2 | LMNA 3376/4885ADRA2A 908/4885CYP2D6 373/4885 |
| US-20050207972-A1 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BRDT, AADAC, IDH2 | LMNA 3376/4885ADRA2A 908/4885CYP2D6 373/4885 |
| US-20060235035-A1 | Novel methoxybenzamibe compounds for use in mch receptor related disorders | GPR119, MCHR2, HCRTR2 | LMNA 3546/4885ADRA2A 213/4885CYP2D6 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.